Jason Politi - 26 Jun 2024 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Technical Ops. Off.
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Jason Politi
Issuer symbol
VERV
Transactions as of
26 Jun 2024
Net transactions value
$0
Form type
3
Filing time
28 Jun 2024, 07:30:05 UTC
Next filing
10 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VERV Common Stock 6,266 26 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Stock Option (right to buy) 26 Jun 2024 Common Stock 118,796 $8.24 Direct F1
holding VERV Stock Option (right to buy) 26 Jun 2024 Common Stock 69,000 $30.94 Direct F2
holding VERV Stock Option (right to buy) 26 Jun 2024 Common Stock 53,170 $21.76 Direct F3
holding VERV Restricted Stock Units 26 Jun 2024 Common Stock 9,945 Direct F4, F8
holding VERV Stock Option (right to buy) 26 Jun 2024 Common Stock 25,000 $11.57 Direct F5
holding VERV Stock Option (right to buy) 26 Jun 2024 Common Stock 90,000 $12.75 Direct F6
holding VERV Restricted Stock Units 26 Jun 2024 Common Stock 22,000 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 19, 2021. 25% of the shares underlying the option vested on February 25, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 25, 2025.
F2 The option was granted on February 11, 2022. 25% of the shares underlying the option vested on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026.
F3 The option was granted on February 14, 2023. 25% of the shares underlying the option vested on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.
F4 On February 14, 2023, the reporting person was granted 13,260 restricted stock units, vesting in four equal annual installments that began on April 1, 2024 and the remaining three installments vesting on April 1, 2025, April 1, 2026 and April 1, 2027.
F5 The option was granted on October 16, 2023. 25% of the shares underlying the option will vest on October 16, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until October 16, 2027.
F6 The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
F7 On February 14, 2024, the reporting person was granted 22,000 restricted stock units, vesting in four equal annual installments beginning on April 1, 2025 and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.
F8 Each restricted stock unit represents a contingent right to receive one share of common stock.

Remarks:

Exhibit Index 24.1 Power of Attorney